Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials

American Heart Journal

Volumn 146, Issue 5, 2003, Pages 848-853

  Haas, Steven Joseph ^a   Vos, Theo ^b   Gilbert, Richard E ^c   Krum, Henry ^a,b  

^a NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL; PLACEBO;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0242720682     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00403-4     Document Type: Article

References (36)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035-8.
2. Iribarren C, Karter AJ, Go AS. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668-73.
3. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001;1:181-93.
4. Chen YT, Vaccarino V, Williams CS. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999;106:605-12.
5. Mosterd A, Hoes AW, de Bruyne MC. Prevalence of heart failure and left ventricular dysfunction in the general population; the Rotterdam Study. Eur Heart J 1999;20:447-55.
6. Croft JB, Giles WH, Pollard RA. National trends in the initial hospitalization for heart failure. J Am Geriatr Soc 1997;45:270-5.
7. Brown AM, Cleland JG. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J 1998;19:1063-9.
8. Shindler DM, Kostis JB, Yusuf S. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017-20.
9. Ryden L, Armstrong PW, Cleland JG. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: results from the AT-LAS trial. Eur Heart J 2000;21:1967-78.
10. Dries DL, Sweitzer NK, Drazner MH. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001;38: 421-8.
11. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334: 1349-55.
12. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
13. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
14. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
15. Packer M, Coats AJ, Fowler MB. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
16. Lessem JN, Weber MA. Antihypertensive treatment with a dual-acting beta-blocker in the elderly. J Hypertens Suppl 1993;11: S29-36.
17. Mohacsi P, Fowler MB, Krum H. Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study. Circulation 2001;104:II-754.
18. Sawicki PT, Siebenhofer A. Beta-blocker treatment in diabetes mellitus. J Intern Med 2001;250:11-7.
19. Sterne JAC, Bradburn MJ, Egger M. Meta-analysis in Stata. In: Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ Publishing Group; 2001. p. 347-69.
20. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman GD, editor. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ Publishing Group; 2001. p. 285-312.
21. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
22. Chavey WE II, Blaum CS, Bleske BE. Guideline for the management of heart failure caused by systolic dysfunction: part II. Treatment. Am Fam Physician 2001;64:1045-54.
23. Lavine SJ, Gellman SD. Treatment of heart failure in patients with diabetes mellitus. Drugs 2002;62:285-307.
24. Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive heart failure: further knowledge needed. Eur Heart J 1999;20: 789-95.
25. Gilbert R, Phillips P, Clarke C. Day-night blood pressure variation in normotensive, normoalbuminuric type I diabetic subjects: dippers and non-dippers. Diabetes Care 1994;17:824-7.
26. Kondo K, Matsubara T, Nakamura J. Characteristic patterns of circadian variation in plasma catecholamine levels, blood pressure and heart rate variability in type 2 diabetic patients. Diabetes Med 2002;19:359-65.
27. Burger AJ, Aronson D. Blunted sympathetic response in diabetic patients with decompensated congestive heart failure. Int J Cardiol 2001;81:243-9.
28. Jacob S, Balletshofer B, Henriksen EJ. Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers. Blood Press 1999;8:261-8.
29. Krum H. Sympathetic activation and the role of beta-blockers in chronic heart failure. Aust N Z J Med 1999;29:418-27.
30. Cardillo C, Campia U, Bryant MB. Increased activity of endogenous endothelin in patients with type Il diabetes mellitus. Circulation 2002;106:1783-7.
31. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc Res 2000;47:457-64.
32. Young JB, Dickerson R, Angel M. Heart failure in the community: clinical trials do not represent the real challenge. Circulation 1999;100:I-538.
33. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002;162:1682-8.
34. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
35. Waagstein F, Bristow MR, Swedberg K. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342: 1441-6.
36. Flather MD, Farkouh ME, Pogue JM. Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials 1997;18:568-79, 661-6.